MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s40164-021-00203-8

Медицинская библиотека · Experimental hematology & oncology · 2021

Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma.

Johnston Patrick B, Cashen Amanda F, Nikolinakos Petros G, Beaven Anne W, Barta Stefan Klaus, Bhat Gajanan, Hasal Steven J, De Vos Sven, Oki Yasuhiro, Deng Changchun, Foss Francine M

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) of belinostat combined with CHOP (Bel-CHOP). Secondary objectives included safety/tolerability, overall response rate (ORR), and belinostat pharmacokinetics (PK).

METHODS

Patients were ≥ 18 years with histologically confirmed, previously untreated PTCL. Patients received belinostat (1000 mg/m2 once daily) + standard CHOP for 6 cycles with varying schedules using a 3 + 3 design in Part A. Part B enrolled patients at MTD dose.

RESULTS

Twenty-three patients were treated. One patient experienced DLT (Grade 3 non-hematologic toxicity) on Day 1-3 schedule, resulting in escalation to Day 1-5 schedule (n = 3). No DLTs were observed and Day 1-5 schedule with 1000 mg/m2 was declared as MTD. Twelve additional patients were enrolled in Part B using MTD. Median relative dose intensity was 98%. All patients experienced adverse events (AEs), including nausea (78%), fatigue (61%), and vomiting (57%). Serious AEs occurred in 43%, with febrile neutropenia (17%) and pyrexia (13%). Overall ORR was 86% with 71% reported CR at MTD. Belinostat PK parameters were similar to single-agent.

CONCLUSIONS

Bel-CHOP was well tolerated and MTD in CHOP combination was the same dose and schedule as single agent dosing.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01839097.

Для цитирования: Johnston Patrick B, Cashen Amanda F, Nikolinakos Petros G, Beaven Anne W, Barta Stefan Klaus, Bhat Gajanan, Hasal Steven J, De Vos Sven, Oki Yasuhiro, Deng Changchun, Foss Francine M. Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma.. Experimental hematology & oncology. 2021. DOI: 10.1186/s40164-021-00203-8.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.